Innate Pharma SA

Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
  • TickerIPH
  • ISINFR0010331421
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Matthieu DRIOL

Short term view - INNATE PHARMA SA : Prices are making further progress.

The trend is bullish. Prices are making further progress. The targets are at €9.000 and then €9.720. The break of €4.554 would endanger the trend.

Matthieu DRIOL

Analyse court terme - INNATE PHARMA SA : La progression des cours se poursuit.

La tendance est haussière. La progression des cours se poursuit. Les objectifs sont à 9,000 € puis 9,720 €. La rupture de 4,554 € mettrait la tendance en danger.

1 director sold

A director at Innate Pharma sold 18,000 shares at 7.430EUR and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Eric Le Berrigaud

INNATE PHARMA BUY | EUR15.8 vs. EUR19.7 Reflecting a new fully-integrated biopharma company into the model

Lumoxiti deal is game-changing from many aspects Lumoxiti will prepare for other launches in the same space It is status-changing for Innate Pharma Our FV derives from the new company structure

Eric Le Berrigaud

INNATE PHARMA Transformative new agreement with AZ

Transformative new agreement with AZ AZ obtains full oncology rights to monalizumab Innate acquires rights to Lumoxiti USD50m upfront payment, milestones, royalties for anti-CD39 AZ acquires 9.8% of Innate at EUR10 per share

Hana Maalej ...
  • Oussema Denguir
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 10/23/2018

...

Oussema Denguir ...
  • Pierre Corby

Innate Pharma : A new transformative deal with Astrazeneca: Buy vs Neutral

>Asset swap with AstraZeneca: Innate will start to market products! - This morning, Innate Pharma has announced a new transformative deal with its partner Astrazeneca. Under the terms of the agreement: 1/ Innate acquires the sales rights for Lumoxiti in the US and Europe (moxetumomab pasudotox-tdfk), a treatment for HC leukemia – a rare disease with around 1000 cases per year in the US. This treatment is developed by AstraZeneca and was approved by the FDA on 13 Septe...

Hana Maalej ...
  • Oussema Denguir
  • Pierre Corby

ODDO BHF Small & MIDCAP MORNING NEWS - 23/10/2018

...

1 director sold

A director at Innate Pharma sold 18,000 shares at 7.430EUR and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

INNATE PHARMA sees a downgrade to Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of INNATE PHARMA (FR), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date September 21, 2018, the closing price was EUR 4.65 and its target price was estimated at EUR 3.20.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

GlobalData Department

Innate Pharma SA (IPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary Innate Pharma SA (Innate Pharma) is a healthcare products provider that develops immunopharmacology and antibody technology products. The company carries out the discovery and development of therapeutic antibodies for the treatment of cancer and inflammatory diseases. It develops new monoclonal antibodies that targets receptors and pathways in controlling the activation of innate immunity cells. The company's pipeline products comprise lirilumab, monalizumab, IPH4102, IPH4301, IPH52, IPH53 and IPH33. It has collaborations and partnerships with academic laboratories, clinical centers a...

Jehanne Leroy

Proxy Report - 29/05/2018

Le principal sujet de la présente assemblée est la résolution 33 qui propose la création d'un droit de vote double alors même que la société avait proposé en 2015 une résolution afin de maintenir le principe "Une Action - Une Voix".  Proxinvest considère que le droit de vote double est une rupture grave du principe d'égalité des actionnaires. Cette rupture de l’égalité entre les actionnaires est double puisque, dans un premier temps, les actionnaires au nominatif et ceux au porteur ne sont plus soumis aux mêmes traitements, les actionnaires au porteur n’ayant aucune possibilité d’accéder au d...

Jehanne Leroy

Etude de l'AG du 23/06/2017

Les deux principaux sujets de la présente assemblée sont d'une part le renouvellement de tous les membres du conseil (résolutions 6 à 13) ainsi que les rémunérations (résolutions 16 à 24 et 26 à 31). Le recours à une structure duale assure la séparation des fonctions entre direction et supervision, le conseil est en majorité indépendant (62,5%) et aucun membre ne semble être en situation de cumul de mandat. Ainsi, tous les renouvellements et nominations proposés sont soutenus. Concernant les rémunérations, la principale faiblesse identifiée demeure le Golden Hello tel que pratiqué par la soc...

Matthieu DRIOL

Short term view - INNATE PHARMA SA : Prices are making further progress.

The trend is bullish. Prices are making further progress. The targets are at €9.000 and then €9.720. The break of €4.554 would endanger the trend.

Matthieu DRIOL

Analyse court terme - INNATE PHARMA SA : La progression des cours se poursuit.

La tendance est haussière. La progression des cours se poursuit. Les objectifs sont à 9,000 € puis 9,720 €. La rupture de 4,554 € mettrait la tendance en danger.

Matthieu DRIOL

Short term view - INNATE PHARMA SA : The trend is bullish.

The trend is bullish. Prices are making further progress. The targets are at €9.000 and then €9.720. The break of €4.554 would endanger the trend.

Matthieu DRIOL

Analyse court terme - INNATE PHARMA SA : La tendance est haussière.

La tendance est haussière. La progression des cours se poursuit. Les objectifs sont à 9,000 € puis 9,720 €. La rupture de 4,554 € mettrait la tendance en danger.

Valérie GASTALDY

Analyse moyen terme - INNATE PHARMA SA : Le rebond gagne en vigueur.

La tendance est baissière. Le rebond gagne en vigueur. Il est probable que cette reprise s'achève sur la résistance à 6,900 € et que les prix baissent à nouveau vers 4,171 €. La tendance de fond serait remise en cause en cas de franchissement de 6,900 €.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch